Coeptis Therapeutics Holdings, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Coeptis Therapeutics Holdings, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q2 2024.
  • Coeptis Therapeutics Holdings, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$3.04M, a 5.22% increase year-over-year.
  • Coeptis Therapeutics Holdings, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$16.1M, a 18.3% increase year-over-year.
  • Coeptis Therapeutics Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$21.3M, a 43.4% increase from 2022.
  • Coeptis Therapeutics Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$37.6M, a 179% decline from 2021.
  • Coeptis Therapeutics Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$13.4M, a 22.2% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$16.1M -$3.04M +$167K +5.22% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-16
Q1 2024 -$16.3M -$3M +$4.96M +62.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-16
Q4 2023 -$21.3M -$3.76M -$813K -27.6% Oct 1, 2023 Dec 31, 2023 10-K/A 2024-08-16
Q3 2023 -$20.5M -$6.35M -$702K -12.4% Jul 1, 2023 Sep 30, 2023 10-Q/A 2024-08-16
Q2 2023 -$19.8M -$3.2M +$6.6M +67.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-16
Q1 2023 -$26.4M -$7.96M +$11.2M +58.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-16
Q4 2022 -$37.6M -$2.94M +$27M +90.2% Oct 1, 2022 Dec 31, 2022 10-K/A 2024-08-16
Q3 2022 -$64.5M -$5.65M -$9.83M -235% Jul 1, 2022 Sep 30, 2022 10-Q/A 2024-08-16
Q2 2022 -$54.7M -$9.8M -$8M -443% Apr 1, 2022 Jun 30, 2022 10-Q/A 2024-08-16
Q1 2022 -$46.7M -$19.2M -$33.3M -236% Jan 1, 2022 Mar 31, 2022 10-Q/A 2024-08-16
Q4 2021 -$13.4M -$29.9M -$12.6M -73% Oct 1, 2021 Dec 31, 2021 10-K/A 2024-03-25
Q3 2021 -$833K $4.18M +$4.18M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-18
Q2 2021 -$5.01M -$1.8M -$1.8M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$3.21M $14.1M +$14.1M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$17.3M -$17.3M Oct 1, 2020 Dec 31, 2020 10-K 2022-04-08
Q3 2020 -$50* -$52 Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-16
Q2 2020 -$450* +$226 Apr 1, 2020 Jun 30, 2020 10-Q 2021-09-14
Q1 2020 $2.00* +$352 Jan 1, 2020 Mar 31, 2020 10-Q 2021-07-30
Q3 2019 $2.00* Jul 1, 2019 Sep 30, 2019 10-Q 2020-12-10
Q2 2019 -$676* Apr 1, 2019 Jun 30, 2019 10-Q 2020-12-10
Q1 2019 -$350* Jan 1, 2019 Mar 31, 2019 10-Q 2020-12-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.